| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 458 | 2021 |
| Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis E Kyriazopoulou, T Huet, G Cavalli, A Gori, M Kyprianou, P Pickkers, ... The Lancet Rheumatology 3 (10), e690-e697, 2021 | 147 | 2021 |
| Risk Factors and Outcomes Associated with Acquisition of Colistin-Resistant KPC-Producing Klebsiella pneumoniae: a Matched Case-Control Study O Zarkotou, S Pournaras, E Voulgari, G Chrysos, A Prekates, D Voutsinas, ... Journal of clinical microbiology 48 (6), 2271-2274, 2010 | 140 | 2010 |
| Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial E Kyriazopoulou, L Liaskou-Antoniou, G Adamis, A Panagaki, ... American Journal of Respiratory and Critical Care Medicine 203 (2), 202-210, 2021 | 104 | 2021 |
| Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms JD Williams, JP Maskell, H Shain, G Chrysos, AM Sefton, HY Fraser, ... Journal of Antimicrobial Chemotherapy 30 (1), 27-37, 1992 | 94 | 1992 |
| Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin D Paraskevis, E Magiorkinis, G Magiorkinis, V Sypsa, V Paparizos, ... The Journal of infectious diseases 196 (8), 1167-1176, 2007 | 79 | 2007 |
| Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries HIV-CAUSAL Collaborationa Clinical Infectious Diseases 54 (9), 1364-1372, 2012 | 73 | 2012 |
| Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study I Karaiskos, GL Daikos, A Gkoufa, G Adamis, A Stefos, S Symbardi, ... Journal of Antimicrobial Chemotherapy 76 (3), 775-783, 2021 | 67 | 2021 |
| Predictors of CD 4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion OT Stirrup, AJ Copas, AN Phillips, MJ Gill, RB Geskus, G Touloumi, ... HIV medicine 19 (3), 184-194, 2018 | 58 | 2018 |
| Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece G Touloumi, N Kalpourtzi, V Papastamopoulos, V Paparizos, G Adamis, ... PLoS One 15 (3), e0230730, 2020 | 41 | 2020 |
| Body composition changes in protease inhibitor‐naive HIV‐infected patients treated with two nucleoside reverse transcriptase inhibitors G Tsekes, G Chrysos, G Douskas, D Paraskeva, N Mangafas, ... HIV medicine 3 (2), 85-90, 2002 | 40 | 2002 |
| Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003–2015: Transmitted drug resistance is due to onward transmissions D Paraskevis, E Kostaki, G Magiorkinis, P Gargalianos, G Xylomenos, ... Infection, Genetics and Evolution 54, 183-191, 2017 | 35 | 2017 |
| Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers F Chereau, Y Madec, C Sabin, N Obel, E Ruiz-Mateos, G Chrysos, ... PloS one 12 (4), e0173893, 2017 | 33 | 2017 |
| Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy N Pantazis, V Papastamopoulos, V Paparizos, S Metallidis, G Adamis, ... Aids 33 (10), 1645-1655, 2019 | 23 | 2019 |
| Coxsackievirus infection associated with acute pancreatitis G Chrysos, S Kokkoris, J Protopsaltis, P Korantzopoulos, G Giannoulis JOP 5 (5), 384-387, 2004 | 22 | 2004 |
| HIV-1 infection in persons homozygous for CCR5-Δ32 allele: the next case and the review J Smoleń-Dzirba, M Rosińska, J Janiec, M Beniowski, M Cycoń, ... AIDS reviews 19 (4), 219-230, 2017 | 20 | 2017 |
| HIV incidence in the Estonian population in 2013 determined using the HIV‐1 limiting antigen avidity assay P Soodla, R Simmons, K Huik, M Pauskar, EL Jõgeda, H Rajasaar, ... HIV medicine 19 (1), 33-41, 2018 | 19 | 2018 |
| Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals G Touloumi, V Paparizos, H Sambatakou, O Katsarou, G Chrysos, ... HIV Clinical Trials 2 (1), 6-16, 2001 | 19 | 2001 |
| Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label single-arm trial K Tsiakos, A Tsakiris, G Tsibris, PM Voutsinas, P Panagopoulos, ... Infectious Diseases and Therapy 10 (4), 2333-2351, 2021 | 16 | 2021 |
| TCR meta-clonotypes for biomarker discovery with tcrdist3: identification of public, HLA-restricted SARS-CoV-2 associated TCR features K Mayer-Blackwell, S Schattgen, L Cohen-Lavi, JC Crawford, A Souquette, ... BioRxiv, 2021 | 16 | 2021 |
